Aptamer-Mediated Transparent-Biocompatible Nanostructured Surfaces for Hepotocellular Circulating Tumor Cells Enrichment.
Aptamer-Mediated Transparent-Biocompatible Nanostructured Surfaces for Hepotocellular Circulating Tumor Cells Enrichment.
复制标题
适体介导的透明生物相容性纳米结构表面用于富集肝细胞循环肿瘤细胞
DOI：
10.7150/thno.15284
复制
发表时间：
2016
期刊：
影响因子：
12.4
通讯作者：
Xiong B
中科院分区：
文献类型：
--
作者：
Wang S;Zhang C;Wang G;Cheng B;Wang Y;Chen F;Chen Y;Feng M;Xiong B
循环肿瘤细胞（CTC）被认为是肿瘤转移的起源。因此，外周血中CTC的检测在不同类型的实体肿瘤中具有重要价值。然而，由于CTC的丰度极低，检测它们在技术上具有挑战性。为了建立一种简单有效的检测肝细胞癌（HCC）患者CTCs的方法，我们应用生物相容性和透明的HA/CTS（羟基磷灰石/壳聚糖）纳米膜，以实现与纳米级细胞表面成分的增强的地形相互作用，我们使用sLex-AP（碳水化合物唾液酸刘易斯X的适体）涂覆到HA/CTS纳米膜上以有效捕获HCC CTC，这两个功能组件结合在一起形成了我们的CTC-BioTChip平台。利用该平台，我们实现了肝癌细胞癌细胞的捕获和识别，在每个加标水平下的平均回收率为61.6%以上。重要的是，我们的平台在42例HCC患者中的25例（59.5%）中鉴定出CTC（2±2/2 mL）。CTCs的阳性率和检出数与肿瘤大小、门静脉癌栓、TNM分期密切相关。综上所述，我们的CTC-BioTChip平台提供了一种新的方法，可以简单而有效地检测HCC患者中的CTC，并且在未来监测HCC预后和指导个体化治疗方面具有临床实用性。
Circulating tumor cells (CTCs) have been considered as the origin of cancer metastasis. Thus, detection of CTCs in peripheral blood is of great value in different types of solid tumors. However, owing to extremely low abundance of CTCs, detection of them has been technically challenging. To establish a simple and efficient method for CTCs detection in patients with hepatocellular carcinoma (HCC), we applied biocompatible and transparent HA/CTS (Hydroxyapatite/chitosan) nanofilm to achieve enhanced topographic interactions with nanoscale cellular surface components, and we used sLex-AP (aptamer for carbohydrate sialyl Lewis X) to coat onto HA/CTS nanofilm for efficient capture of HCC CTCs, these two functional components combined to form our CTC-BioTChip platform. Using this platform, we realized HCC CTCs' capture and identification, the average recovery rate was 61.6% or more at each spiking level. Importantly, our platform identified CTCs (2±2 per 2 mL) in 25 of 42 (59.5%) HCC patients. Moreover, both the positivity rate and the number of detected CTCs were significantly correlated with tumor size, portal vein tumor thrombus, and the TNM (tumor-node-metastasis) stage. In summary, our CTC-BioTChip platform provides a new method allowing for simple but efficient detection of CTCs in HCC patients, and it holds potential of clinically usefulness in monitoring HCC prognosis and guiding individualized treatment in the future.